Intellia Therapeutics (NTLA) Change in Receivables (2016 - 2026)
Intellia Therapeutics' (NTLA) quarterly Change in Receivables came in at -$337000.0 in Q1 2026, down 116.96% year-on-year from $2.0 million in Q1 2025, and up 78.7% on a QoQ basis from -$1.6 million in Q4 2025.
Intellia Therapeutics (NTLA) Change in Receivables (2016 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has 11 years of Change in Receivables data on file, last reported at -$337000.0 in Q1 2026.
- On a quarterly basis, Change in Receivables fell 116.96% year-over-year to -$337000.0 in Q1 2026; TTM through Mar 2026 was -$1.4 million, a 94.7% increase from a year earlier, with the FY2025 full-year figure at $951000.0, up 103.4% from the prior year.
- Change in Receivables for Q1 2026 stood at -$337000.0, up from -$1.6 million in the prior quarter.
- Over the last five years, Change in Receivables for NTLA reached as high as $30.0 million in Q4 2023 and fell as low as -$24.1 million in Q2 2024.
- Historically, Change in Receivables has averaged $417647.1 across 5 years, with a median of -$29000.0 in 2024.
- Across the five-year window, Change in Receivables surged 11850.98% in 2023 and sank 16059.6% in 2024, its largest moves.
- Year by year, Change in Receivables stood at -$255000.0 in 2022, then jumped by 11850.98% to $30.0 million in 2023, then plunged by 101.12% to -$337000.0 in 2024, then slumped by 369.44% to -$1.6 million in 2025, then surged by 78.7% to -$337000.0 in 2026.
- Per Business Quant data, the three most recent Change in Receivables figures were -$337000.0 in Q1 2026, -$1.6 million in Q4 2025, and -$303000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 75.30 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Intellia Therapeutics | 1.27 Bn | 1.27 Bn | - | -337,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -337,000.00 |
| Mar 31, 2026 | -337,000.00 |
| Dec 31, 2025 | -1.58 Mn |
| Dec 31, 2025 | -1.58 Mn |
| Sep 30, 2025 | -303,000.00 |
| Sep 30, 2025 | -303,000.00 |
| Jun 30, 2025 | 849,000.00 |
| Jun 30, 2025 | 849,000.00 |
| Mar 31, 2025 | 1.99 Mn |
| Mar 31, 2025 | 1.99 Mn |
| Dec 31, 2024 | -337,000.00 |
| Dec 31, 2024 | -337,000.00 |
| Sep 30, 2024 | -3.47 Mn |
| Sep 30, 2024 | -3.47 Mn |
| Jun 30, 2024 | -24.10 Mn |
| Jun 30, 2024 | -24.10 Mn |
| Mar 31, 2024 | -29,000.00 |
| Mar 31, 2024 | -29,000.00 |
| Dec 31, 2023 | 29.97 Mn |
| Dec 31, 2023 | 29.97 Mn |